Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria
- PMID: 10199430
- DOI: 10.1001/jama.281.13.1203
Relationship between fasting plasma glucose and glycosylated hemoglobin: potential for false-positive diagnoses of type 2 diabetes using new diagnostic criteria
Erratum in
- JAMA 1999 Jun 16;281(23):2187
Abstract
Context: New criteria for the diagnosis of type 2 diabetes mellitus have recently been introduced that lowered the diagnostic fasting plasma glucose (FPG) concentration from 7.8 to 7.0 mmol/L (140 to 126 mg/dL).
Objective: To determine if individuals with diabetes diagnosed by the new FPG concentration criterion would have excessive glycosylation (elevated hemoglobin [HbA1c] levels).
Definitions: We determined the distribution of HbA1c levels in individuals using 4 classifications: (1) normal by the new criterion (FPG concentration <6.1 mmol/L [110 mg/dL]); (2) impaired fasting glucose by the new criterion (FPG concentration of 6.1-6.9 mmol/L [110-125 mg/dL]); (3) diabetes diagnosed solely by the new FPG concentration criterion of 7.0 through 7.7 mmol/L (126-139 mg/dL); and (4) diabetes diagnosed by the previous FPG concentration criterion of 7.8 mmol/L (140 mg/dL) or higher.
Design: Cross-sectional analysis of 2 large data sets (NHANES III and Meta-Analysis Research Group [MRG] on the Diagnosis of Diabetes Using Glycated Hemoglobin) that contained individuals in whom FPG concentrations, 2-hour glucose concentrations using an oral glucose tolerance test, and an HbA1c level were simultaneously measured. We cross-tabulated FPG concentrations (<6.1 mmol/L [110 mg/dL], 6.1-6.9 mmol/L [110-125 mg/dL], 7.0-7.7 mmol/L [126-139 mg/dL], and > or =7.8 mmol/L [140 mg/dL]) and HbA1c levels separated into 3 intervals: normal, less than the upper limit of normal (ULN); slightly elevated, ULN to ULN plus 1%; and high, higher than ULN plus 1%.
Results: Among subjects with normal FPG concentrations, HbA1c levels in the NHANES III (and the MRG) data sets were normal in 97.3% (96.2%), slightly elevated in 2.7% (3.6%), and high in 0.1% (0.2%). Among individuals with impaired fasting glucose, HbA1c concentrations were normal in 86.7% (81.4%), slightly elevated in 13.1% (16.4%), and high in 0.2% (2.2%). Among diabetic patients diagnosed by the new FPG criterion only, HbA1c levels were normal in 60.9% (59.6%), slightly elevated in 35.8% (32.8%), and high in 3.4% (7.6%). In diabetic patients diagnosed by the former FPG criterion, HbA1c levels were normal in 18.6% (16.7%), slightly elevated in 32.5% (21.0%), and high in 48.9% (62.3%).
Conclusions: About 60% of the new cohort of diabetic patients in both data sets have normal HbA1c levels. We believe that diabetes should not be diagnosed in those with FPG concentrations less than 7.8 mmol/L (140 mg/dL) unless excessive glycosylation is evident. Individuals without excessive glycosylation but with moderate elevations of FPG concentrations (6.1-7.7 mmol/L [110-139 mg/dL]) should be diagnosed as having impaired fasting glucose and treated with an appropriate diet and exercise. This diagnostic labeling achieves the goal of early intervention without subjecting these persons to the potentially negative insurance, employment, social, and psychological consequences of a diagnosis of diabetes mellitus.
Comment in
-
When is diabetes diabetes?JAMA. 1999 Apr 7;281(13):1222-4. doi: 10.1001/jama.281.13.1222. JAMA. 1999. PMID: 10199434 No abstract available.
-
Glycosylated hemoglobin as a diagnostic test for type 2 diabetes mellitus.JAMA. 2000 Feb 2;283(5):605-6. doi: 10.1001/jama.283.5.605. JAMA. 2000. PMID: 10665697 No abstract available.
-
Glycosylated hemoglobin as a diagnostic test for type 2 diabetes mellitus.JAMA. 2000 Feb 2;283(5):606. JAMA. 2000. PMID: 10665698 No abstract available.
Similar articles
-
HbA1c measurement improves the detection of type 2 diabetes in high-risk individuals with nondiagnostic levels of fasting plasma glucose: the Early Diabetes Intervention Program (EDIP).Diabetes Care. 2001 Mar;24(3):465-71. doi: 10.2337/diacare.24.3.465. Diabetes Care. 2001. PMID: 11289469 Clinical Trial.
-
Combined use of a fasting plasma glucose concentration and HbA1c or fructosamine predicts the likelihood of having diabetes in high-risk subjects.Diabetes Care. 1998 Aug;21(8):1221-5. doi: 10.2337/diacare.21.8.1221. Diabetes Care. 1998. PMID: 9702423
-
Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.Diabetes Res Clin Pract. 2002 Jan;55(1):65-85. doi: 10.1016/s0168-8227(01)00365-5. Diabetes Res Clin Pract. 2002. PMID: 11755481
-
Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.Cochrane Database Syst Rev. 2018 Oct 29;10(10):CD012661. doi: 10.1002/14651858.CD012661.pub2. Cochrane Database Syst Rev. 2018. PMID: 30371961 Free PMC article.
-
Postprandial peaks as a risk factor for cardiovascular disease: epidemiological perspectives.Int J Clin Pract Suppl. 2002 Jul;(129):5-11. Int J Clin Pract Suppl. 2002. PMID: 12166607 Review.
Cited by
-
What explains the American disadvantage in health compared with the English? The case of diabetes.J Epidemiol Community Health. 2012 Mar;66(3):259-64. doi: 10.1136/jech.2010.108415. Epub 2010 Oct 1. J Epidemiol Community Health. 2012. PMID: 20889587 Free PMC article.
-
Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the U.S. population: Implications for diabetes diagnostic thresholds.Diabetes Care. 2009 Nov;32(11):2027-32. doi: 10.2337/dc09-0440. Diabetes Care. 2009. PMID: 19875604 Free PMC article.
-
The inverse benefit law: how drug marketing undermines patient safety and public health.Am J Public Health. 2011 Mar;101(3):399-404. doi: 10.2105/AJPH.2010.199844. Epub 2011 Jan 13. Am J Public Health. 2011. PMID: 21233426 Free PMC article.
-
Diagnosing diabetes with glucose criteria: worshiping a false God.Diabetes Care. 2011 Feb;34(2):524-6. doi: 10.2337/dc10-1689. Diabetes Care. 2011. PMID: 21270208 Free PMC article. No abstract available.
-
Humanin: a mitochondrial signaling peptide as a biomarker for impaired fasting glucose-related oxidative stress.Physiol Rep. 2016 May;4(9):e12796. doi: 10.14814/phy2.12796. Physiol Rep. 2016. PMID: 27173674 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical